• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration.免疫吸附与血浆置换及联合治疗用于重症肌无力病情恶化的治疗比较
Ther Adv Neurol Disord. 2016 Jul;9(4):297-303. doi: 10.1177/1756285616637046. Epub 2016 Mar 10.
2
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.一项比较免疫吸附与血浆置换治疗重症肌无力危象的随机对照研究。
J Clin Apher. 2011 Dec;26(6):347-55. doi: 10.1002/jca.20317. Epub 2011 Nov 17.
3
Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.免疫吸附与血浆置换治疗多发性硬化症和临床孤立综合征激素抵抗性复发的安全性和有效性:一项随机、平行组、对照试验。
EClinicalMedicine. 2019 Nov 14;16:98-106. doi: 10.1016/j.eclinm.2019.10.017. eCollection 2019 Nov.
4
Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases.血浆置换和免疫吸附在神经炎症性疾病中的安全性和耐受性
J Clin Med. 2020 Sep 5;9(9):2874. doi: 10.3390/jcm9092874.
5
Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.格林-巴利综合征和重症肌无力中的免疫吸附
Ther Apher. 2000 Jun;4(3):195-7. doi: 10.1046/j.1526-0968.2000.00183.x.
6
Safety of Therapeutic Apheresis in Children and Adolescents.儿童和青少年治疗性血液成分单采的安全性
Front Pediatr. 2022 Apr 12;10:850819. doi: 10.3389/fped.2022.850819. eCollection 2022.
7
Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study.重症肌无力中淋巴细胞去除术与血浆置换的比较:一项回顾性队列研究
Front Neurol. 2023 Jun 27;14:1212868. doi: 10.3389/fneur.2023.1212868. eCollection 2023.
8
Long-term treatment of myasthenia gravis with immunoadsorption.免疫吸附法对重症肌无力的长期治疗
J Clin Apher. 2002;17(2):84-7. doi: 10.1002/jca.10023.
9
Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.类固醇难治性多发性硬化症中的免疫吸附:60例患者的临床经验
Atheroscler Suppl. 2013 Jan;14(1):167-73. doi: 10.1016/j.atherosclerosissup.2012.10.025.
10
Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.比较三种降低AB0血型不相容肾移植受者同种凝集素效价技术的疗效。
Atheroscler Suppl. 2017 Nov;30:253-256. doi: 10.1016/j.atherosclerosissup.2017.05.017. Epub 2017 Jun 1.

引用本文的文献

1
Successful Emergency Management of a Dog with Ventilator-Dependent Acquired Myasthenia Gravis with Immunoadsorption.通过免疫吸附成功急诊处理一只依赖呼吸机的获得性重症肌无力犬。
Animals (Basel). 2023 Dec 21;14(1):33. doi: 10.3390/ani14010033.
2
Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study.重症肌无力中淋巴细胞去除术与血浆置换的比较:一项回顾性队列研究
Front Neurol. 2023 Jun 27;14:1212868. doi: 10.3389/fneur.2023.1212868. eCollection 2023.
3
Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.重症肌无力:从传统治疗到再生治疗干预的新发现与展望
Aging Dis. 2023 Aug 1;14(4):1070-1092. doi: 10.14336/AD.2022.1215.
4
Principles of Therapeutic Apheresis in Neurological Disease.神经疾病治疗性血液成分单采术的原则
Transfus Med Hemother. 2023 Mar 14;50(2):88-97. doi: 10.1159/000529463. eCollection 2023 Apr.
5
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.免疫吸附与大剂量甲基强的松龙治疗难治性多发性硬化复发的疗效比较
J Neuroinflammation. 2022 Sep 7;19(1):220. doi: 10.1186/s12974-022-02583-y.
6
Total Plasma Exchange in Neuromuscular Junction Disorders-A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis.神经肌肉接头疾病中的全血浆置换——一项关于疗效、安全性及在疑难诊断中潜在诊断特性的单中心回顾性分析
J Clin Med. 2022 Jul 28;11(15):4383. doi: 10.3390/jcm11154383.
7
Advances and challenges in the treatment of myasthenia gravis.重症肌无力治疗的进展与挑战
Ther Adv Neurol Disord. 2021 Dec 21;14:17562864211065406. doi: 10.1177/17562864211065406. eCollection 2021.
8
Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts.肌痛性脑脊髓炎(ME)患者中β-肾上腺素能和毒蕈碱胆碱能受体自身抗体——来自两个瑞典队列的血浆和脑脊液的验证研究
Brain Behav Immun Health. 2020 Jul 18;7:100107. doi: 10.1016/j.bbih.2020.100107. eCollection 2020 Aug.
9
Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.重症肌无力的治疗性血浆置换:比较证据的系统文献综述与荟萃分析
Front Neurol. 2021 Aug 31;12:662856. doi: 10.3389/fneur.2021.662856. eCollection 2021.
10
Apheresis in Neurological Disorders.神经疾病中的血液成分单采术
J Clin Med. 2020 Oct 6;9(10):3211. doi: 10.3390/jcm9103211.

本文引用的文献

1
Scale up and safety parameters of antigen specific immunoadsorption of human anti-acetylcholine receptor antibodies.抗原特异性免疫吸附人抗乙酰胆碱受体抗体的放大和安全参数。
J Neuroimmunol. 2014 Feb 15;267(1-2):1-6. doi: 10.1016/j.jneuroim.2013.11.001. Epub 2013 Nov 10.
2
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.一项比较免疫吸附与血浆置换治疗重症肌无力危象的随机对照研究。
J Clin Apher. 2011 Dec;26(6):347-55. doi: 10.1002/jca.20317. Epub 2011 Nov 17.
3
Advances in the diagnosis, pathogenesis and treatment of CIDP.CIDP 的诊断、发病机制和治疗进展。
Nat Rev Neurol. 2011 Aug 16;7(9):507-17. doi: 10.1038/nrneurol.2011.121.
4
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.抗 LRP4 自身抗体在乙酰胆碱受体抗体和肌肉特异性激酶抗体阴性的重症肌无力中的作用。
J Neurol. 2012 Mar;259(3):427-35. doi: 10.1007/s00415-011-6194-7. Epub 2011 Aug 5.
5
Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.重症肌无力患者的低密度脂蛋白受体相关蛋白 4 自身抗体。
Ann Neurol. 2011 Feb;69(2):418-22. doi: 10.1002/ana.22312.
6
Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.比较双重过滤血浆置换、免疫吸附和静脉注射免疫球蛋白治疗晚发型重症肌无力的自身抗体水平及临床疗效。
Ther Apher Dial. 2010 Apr;14(2):153-60. doi: 10.1111/j.1744-9987.2009.00751.x.
7
Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.实现致病性自身抗体的抗原特异性单采,作为血浆置换治疗重症肌无力的进一步措施。
J Neuroimmunol. 2008 Sep 15;201-202:95-103. doi: 10.1016/j.jneuroim.2008.06.020. Epub 2008 Jul 29.
8
[Rapid physiological coagulation method in determination of fibrinogen].[快速生理凝血法测定纤维蛋白原]
Acta Haematol. 1957 Apr;17(4):237-46. doi: 10.1159/000205234.
9
Long-term treatment of myasthenia gravis with immunoadsorption.免疫吸附法对重症肌无力的长期治疗
J Clin Apher. 2002;17(2):84-7. doi: 10.1002/jca.10023.
10
Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.基于模拟乙酰胆碱受体免疫原性位点的特异性配体的重症肌无力免疫吸附法。
Ther Apher. 2001 Oct;5(5):340-50. doi: 10.1046/j.1526-0968.2001.00367.x.

免疫吸附与血浆置换及联合治疗用于重症肌无力病情恶化的治疗比较

Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration.

作者信息

Schneider-Gold Christiane, Krenzer Marco, Klinker Erdmute, Mansouri-Thalegani Behrouz, Müllges Wolfgang, Toyka Klaus V, Gold Ralf

机构信息

Department of Neurology, University of Würzburg, Würzburg, Germany.

Transfusion Medicine, University of Würzburg, Würzburg, Germany.

出版信息

Ther Adv Neurol Disord. 2016 Jul;9(4):297-303. doi: 10.1177/1756285616637046. Epub 2016 Mar 10.

DOI:10.1177/1756285616637046
PMID:27366236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4916519/
Abstract

OBJECTIVES

The goal of this study was to analyze safety and assess the efficacy of standard plasma exchange (PE) compared with immunoadsorption (IA) alone, or an alternating combination of both in deteriorating myasthenia gravis (MG).

METHODS

A total of 72 patients with MG who had received PE procedures for treatment of severe deterioration were retrospectively analyzed. They received either five cycles of PE (1-1.5 plasma volumes), or five cycles of IA in line with plasma separation, or a sequential alternating procedure of one cycle of PE followed by two cycles of IA, which was repeated once or more if needed.

RESULTS

A total of 19 patients received PE, 24 patients IA, and 29 the alternating combination therapy. All groups were equally distributed by sex and mean MG score before treatment. The number of treatment cycles and days on therapy did not differ between the groups. Mean MG scores at discharge were 3.0 (PE), 1.8 (IA) and 1.6 (combination) (p = 0.028 for combination versus PE). Inpatient time was 30.7 days (PE), 22.3 days (IA) and 20.0 days in combination therapy (p < 0.05 for combination versus PE). Side effects such as allergic reactions or hypocoagulability were significantly more frequent in the PE group (37% in PE versus 4% in IA and 3.6% in the alternating combination, p < 0.05).

CONCLUSION

Semiselective IA in combination with PE, and to a lesser extent IA alone, was associated with a shorter hospital stay and more pronounced reduction of the MG score than PE.

摘要

目的

本研究旨在分析标准血浆置换(PE)与单独免疫吸附(IA)或两者交替联合使用在重症肌无力(MG)病情恶化时的安全性并评估其疗效。

方法

回顾性分析了72例接受PE治疗严重病情恶化的MG患者。他们接受了五个周期的PE(1 - 1.5个血浆容量),或与血浆分离同步的五个周期的IA,或一个周期的PE后接两个周期的IA的序贯交替程序,如有需要可重复一次或多次。

结果

共有19例患者接受PE,24例接受IA,29例接受交替联合治疗。所有组在治疗前按性别和平均MG评分均衡分布。各组之间的治疗周期数和治疗天数无差异。出院时的平均MG评分分别为3.0(PE)、1.8(IA)和1.6(联合治疗)(联合治疗与PE相比,p = 0.028)。住院时间分别为30.7天(PE)、22.3天(IA)和联合治疗组20.0天(联合治疗与PE相比,p < 0.05)。PE组的过敏反应或低凝等副作用明显更常见(PE组为37%,IA组为4%,交替联合组为3.6%,p < 0.05)。

结论

与PE相比,半选择性IA联合PE以及程度较轻的单独IA与住院时间缩短和MG评分更显著降低相关。